This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
INSP Stock Declines Despite Q4 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the fourth quarter.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
The Zacks Analyst Blog The Procter & Gamble, Boston, ConocoPhillips and Kewaunee Scientific
by Zacks Equity Research
The Procter & Gamble, Boston, ConocoPhillips and Kewaunee Scientific are included in this Analyst Blog.
Top Research Reports for Procter & Gamble, Boston Scientific & ConocoPhillips
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Boston Scientific Corporation (BSX) and ConocoPhillips (COP), as well as a micro-cap stock Kewaunee Scientific Corporation (KEQU).
Best Momentum Stocks to Buy for February 10th
by Zacks Equity Research
BSX, ENVA and CFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 10, 2025.
5 Momentum Stocks to Buy for February Amid Volatility
by Nalak Das
These five stocks have strong momentum for February. These are: APH, BSX, NLY, PNFP, FHN.
New Strong Buy Stocks for February 10th
by Zacks Equity Research
PFIS, BSX, ENVA, NFG and NLY have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2025.
Boston Scientific (BSX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Boston Scientific (BSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Has Boston Scientific (BSX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Alphatec (ATEC) have performed compared to their sector so far this year.
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific (BSX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BSX Q4 Earnings & Revenues Top, Stock Falls on Weak Gross Margin
by Zacks Equity Research
Boston Scientific's fourth-quarter 2024 performance reflects the strength of its core franchises.
Boston Scientific (BSX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 7.69% and 3.52%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Boston Scientific, Hologic, BioTechne, STERIS and Align
by Zacks Equity Research
Boston Scientific, Hologic, BioTechne, STERIS and Align are included in this Analyst Blog.
Can These 5 MedTech Stocks Hit Earnings Targets This Season?
by Urmimala Biswas
Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow.
PBH vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
What Analyst Projections for Key Metrics Reveal About Boston Scientific (BSX) Q4 Earnings
by Zacks Equity Research
Evaluate the expected performance of Boston Scientific (BSX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch
by Indrajit Bandyopadhyay
As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.
BSX Pre-Q4 Earnings: To Buy or Not to Buy Boston Scientific Stock Now?
by Urmimala Biswas
Boston Scientific is expected to have registered strong growth in the Asia Pacific in the fourth quarter, led by strength in China and Japan.
Boston Scientific (BSX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific (BSX) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Boston Scientific (BSX) stood at $102.27, denoting a +0.32% change from the preceding trading day.
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed the most recent trading day at $101.64, moving +1.33% from the previous trading session.
Abbott (ABT) Q4 Earnings Meet Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?